Mauritania vs Sao Tome and Principe: The number of people with susceptibility test result for rifampicin
Mauritania
0
in 2021
Sao Tome and Principe
0
in 2021
Mauritania rank
142nd
Sao Tome and Principe rank
142nd
The number of people with susceptibility test result for rifampicin over time
- Mauritania
- Sao Tome and Principe
How they compare
Mauritania currently reports 0 against 0 in Sao Tome and Principe, a difference of 0.
Across all 5 years both countries report, Sao Tome and Principe has been ahead every year.
Mauritania ranks 142nd and Sao Tome and Principe ranks 142nd of 146 countries.
Sao Tome and Principe has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mauritania | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2459 | 20.76 | 20.51 | Sao Tome and Principe |
| 2020s | 0 | 1.04 | 1.04 | Sao Tome and Principe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Mauritania or Sao Tome and Principe?
- Mauritania, at 0 against 0 in Sao Tome and Principe as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Mauritania and Sao Tome and Principe?
- 0, with Mauritania ahead.
- How many years of comparable data are there for Mauritania and Sao Tome and Principe?
- 5 years are reported by both, from 2017 to 2021.
- How do Mauritania and Sao Tome and Principe rank globally for the number of people with susceptibility test result for rifampicin?
- Mauritania ranks 142nd and Sao Tome and Principe ranks 142nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.